301 related articles for article (PubMed ID: 36246941)
1. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
[TBL] [Abstract][Full Text] [Related]
2. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR
Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184
[TBL] [Abstract][Full Text] [Related]
3. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
Ophthalmology; 2024 Feb; ():. PubMed ID: 38382813
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS; Khanani AM; Quezada Ruiz C; Basu K; Ferrone PJ; Brittain C; Figueroa MS; Lin H; Holz FG; Patel V; Lai TYY; Silverman D; Regillo C; Swaminathan B; Viola F; Cheung CMG; Wong TY;
Lancet; 2022 Feb; 399(10326):729-740. PubMed ID: 35085502
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA;
Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Koizumi H; Gomi F; Tsujikawa A; Honda S; Mori R; Ochi H; Iwasaki K; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Mar; ():. PubMed ID: 38483611
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Takahashi K; Cheung CMG; Iida T; Lai TYY; Ohji M; Yanagi Y; Kawano M; Ohsawa S; Suzuki T; Kotecha A; Lin H; Patel V; Swaminathan B; Lee WK;
Graefes Arch Clin Exp Ophthalmol; 2023 Nov; 261(11):3125-3137. PubMed ID: 37294433
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
9. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
10. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
[TBL] [Abstract][Full Text] [Related]
11. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
Penha FM; Masud M; Khanani ZA; Thomas M; Fong RD; Smith K; Chand A; Khan M; Gahn G; Melo GB; Khanani AM
Int J Retina Vitreous; 2024 Jan; 10(1):5. PubMed ID: 38233896
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM; Patel SS; Ferrone PJ; Osborne A; Sahni J; Grzeschik S; Basu K; Ehrlich JS; Haskova Z; Dugel PU
JAMA Ophthalmol; 2020 Sep; 138(9):964-972. PubMed ID: 32729897
[TBL] [Abstract][Full Text] [Related]
13. BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale.
Hattenbach LO; Abreu F; Arrisi P; Basu K; Danzig CJ; Guymer R; Haskova Z; Heier JS; Kotecha A; Liu Y; Loewenstein A; Seres A; Willis JR; Wykoff CC; Paris LP
Ophthalmol Sci; 2023 Sep; 3(3):100302. PubMed ID: 37810589
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R;
Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M; Kitano S; Ogata N; Mitamura Y; Oh H; Ochi H; Ohsawa S; Hirakata A;
Jpn J Ophthalmol; 2023 May; 67(3):264-279. PubMed ID: 36897413
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.
Tadayoni R; Paris LP; Danzig CJ; Abreu F; Khanani AM; Brittain C; Lai TYY; Haskova Z; Sakamoto T; Kotecha A; Schlottmann PG; Liu Y; Seres A; Retiere AC; Willis JR; Yoon YH;
Ophthalmology; 2024 Jan; ():. PubMed ID: 38280653
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Hershberger VS; Pauly-Evers M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Osborne A; Weikert R; Fauser S
Ophthalmology; 2019 Aug; 126(8):1155-1170. PubMed ID: 30905643
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials.
Larsen HO; Grauslund J; Vergmann AS
Ophthalmol Ther; 2023 Oct; 12(5):2253-2264. PubMed ID: 37410309
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
Kodjikian L; Arias Barquet L; Papp A; Kertes PJ; Midena E; Ernest J; Silva R; Schmelter T; Niesen T; Leal S
Adv Ther; 2024 Mar; 41(3):1010-1024. PubMed ID: 38183525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
